A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Jun 2012
At a glance
- Drugs Firtecan pegol (Primary)
- Indications Neuroblastoma; Solid tumours
- Focus Adverse reactions
- 19 Jun 2012 Primary endpoint 'Recommended-phase-II-dose' has been met.
- 19 Jun 2012 Results have been presented at the 2012 Advances in Neuroblastoma Research Conference according to an Enzon Pharmaceuticals media release. Results were also summarised in the media release.
- 07 Mar 2012 Planned End Date changed from 1 Jul 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.